|Institution:||CRUK Manchester Institute|
|Term:||3 years fixed term|
|Salary:||£31,604 - £41,929|
|Line 1:||CRUK Manchester Institute|
About the role:
A 3 year position is available in the laboratory of Professor Tim Somervaille to study the role that transcription factors play in human acute myeloid leukaemia.
The aims of the Leukaemia Biology Group are to identify genes and cellular pathways critical for the function of leukaemia stem cells but not normal haematopoietic stem/progenitor cells (HSPC); to assess their potential as therapeutic targets; and to develop and evaluate compounds inhibiting these targets as an antecedent to early phase clinical trials for the benefit of patients.
You should have a PhD in a relevant biomedical discipline. A background in the biology of leukaemic haematopoiesis is desirable but not required.
Key qualities should include independent thinking, ability to work in a team and good communication skills, all of which are needed to efficiently work in a multidisciplinary team.
Why choose Cancer Research UK Manchester Institute?
The Cancer Research UK Manchester Institute (www.cruk.manchester.ac.uk), an Institute of The University of Manchester (www.manchester.ac.uk), is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (www.cancerresearchuk.org), the largest independent cancer research organisation in the world. We are currently situated at the The Oglesby Cancer Research Building in South Manchester and at the internationally-renowned life sciences campus at Alderley Park in Cheshire England, 15 miles from Manchester, a vibrant and dynamic city surrounded by beautiful countryside.
This post will be based at The Oglesby Cancer Research Building in Withington, across from The Christie NHS Foundation Trust.
We are partnered with The Christie NHS Foundation Trust (adjacent to the CRUK Manchester Institute, Paterson Building) in South Manchester (www.christie.nhs.uk), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.
Our aim is to understand the fundamental basis of cancer and apply that knowledge to developing new treatment strategies for cancer patients. Our advanced research programmes span a spectrum of cancer research, from the molecular and cellular basis of cancer through to drug discovery, translational research and clinical trials.
The Institute has access to outstanding laboratory facilities and exceptional core services, including next generation sequencing, microarrays, confocal microscopy, bioinformatics, histology and mass-spectrometry.